A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation

D. H. Lee, A. Roohullah, B. C. Cho, S-H. Lee, C. Lemech, P. De Souza, M. Millward, J. Choi, K. E. Park, E. Kim, N. Y. Kim, Y. K. Shin, J-Y. Han

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

Original languageEnglish
Pages (from-to)S1096-S1096
Number of pages1
JournalAnnals of Oncology
Issue number7
Publication statusPublished - Sept 2022
Event2022 Annual Meeting of the European-Society-for-Medical-Oncology - , France
Duration: 9 Sept 202213 Sept 2022

Cite this